Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-17-017466
Filing Date
2017-06-28
Accepted
2017-06-28 19:48:00
Documents
1
Period of Report
2017-06-28

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 11196
  Complete submission text file 0000899243-17-017466.txt   13357
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38130 | Film No.: 17936537
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38130 | Film No.: 17936538

Mailing Address 281 ALBANY STREET CAMBRIDGE MA 02139
Business Address 281 ALBANY STREET CAMBRIDGE MA 02139 617-995-0900
AILERON THERAPEUTICS INC (Issuer) CIK: 0001420565 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations